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Abstract
Background: This study sought to investigate the efficacy of duloxetine for the treatment of obsessive-compulsive disorder 
(DSM-IV).
Methods: Twenty individuals were enrolled in a 17-week, open-label trial of duloxetine at Massachusetts General Hospital. 
Data were collected between March 2007 and September 2012. Study measures assessing obsessive-compulsive disorder 
symptoms, quality of life, depression, and anxiety were administered at baseline and weeks 1, 5, 9, 13, and 17. The primary 
outcome measures were the Yale-Brown Obsessive Compulsive Scale and Clinical Global Improvement scale.
Results: For the 12 study completers, pre- and posttreatment analyses revealed significant improvements (P < .05) on clinician- 
and self-rated measures of obsessive-compulsive disorder symptoms and quality of life. Among the 12 completers, more than 
one-half (n = 7) satisfied full medication response criteria. Intention-to-treat analyses (n = 20) showed similar improvements 
(P < .05) on primary and secondary study outcome measures.
Conclusion: The results of this study suggest that duloxetine may provide a significant reduction in symptoms for patients 
with obsessive-compulsive disorder.
ClinicalTrials.gov NCT00464698; http://clinicaltrials.gov/ct2/show/NCT00464698?term=NCT00464698&rank=1.
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Introduction
First-line treatment options for obsessive compulsive disorder 
(OCD) include serotonin reuptake inhibitors (SRIs) and behavio-
ral therapy. Currently, the SRIs are the primary pharmacotherapy 
treatment option for OCD (Dougherty et al., 2004). Multiple ran-
domized, placebo-controlled, double-blind studies support the 
efficacy of SRIs as treatment for OCD (Karabanow et  al., 1977; 
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Montgomery, 1980; Perse et  al., 1987; Goodman et  al., 1989a; 
Jenike et  al., 1990; Goodman et  al., 1996; Kronig et  al., 1999). 
Because serotonergic agents have been shown to be the most 
effective treatment for OCD, serotonin-norepinephrine reuptake 
inhibitors have been studied for the treatment of OCD as well. 
A  small body of evidence supports the efficacy of venlafaxine 
for the treatment of OCD. Previous studies include small open-
label studies (Rauch et al., 1996) and case reports (Zajecks et al., 
1990; Anath et al., 1995; Grossman et al., 1996). One double-blind, 
head-to-head study compared venlafaxine with paroxetine, find-
ing that the agents were equally efficacious (Denys et al., 2003).
Duloxetine, a new serotonin-norepinephrine reuptake inhib-
itor (SNRI), has not yet been studied as a treatment option for 
OCD. It is believed that because duloxetine has strong serotonin 
reuptake inhibition properties, it will be an effective treatment 
for OCD. Monotherapeutic pharmacological treatment is cur-
rently limited to SRIs, so data supporting the use of other agents 
could be of tremendous benefit. This study proposes to assess 
the effects of duloxetine for the treatment of OCD via an open-
label clinical trial in 20 patients with OCD.
Methods
Participants
Twenty participants with OCD were enrolled in a 17-week, open-
label treatment trial with duloxetine. The recruitment occurred 
under supervision of the Massachusetts General Hospital OCD 
Clinic and Research Unit. All study protocols and consents were 
approved by the local institutional review board prior to study 
initiation and enrollment. Subjects were recruited through clini-
cian referrals as well as through hospital-approved advertise-
ments posted in newspapers, on the internet, and on hospital 
bulletin boards. This study was also listed in the ClinicalTrials.
gov registry. All participants signed informed consent state-
ments prior to study engagement.
Participants met the following study inclusion criteria: 
Diagnostic and Statistical Manual of Mental Disorders diag-
nosis of OCD as assessed by the Structured-Clinical Interview 
for Diagnostic and Statistical Manual of Mental Disorders Axis 
I disorders; age between 18 and 65 years; Yale-Brown Obsessive 
Compulsive Scale (Y-BOCS) score >20; written informed consent; 
and negative serum or urinary beta-human chorionic gonado-
tropin test for females of childbearing potential.
Exclusion criteria involved pregnant women or women of 
childbearing potential who were not using medically accepted 
means of contraception; women who were pregnant or breast-
feeding; patients who, in the investigator’s judgment, pose seri-
ous suicidal or homicidal risk; and history of a seizure disorder 
or other serious medical illness. Additional exclusion crite-
ria included anticoagulant therapy or other medications that 
might interfere with duloxetine and patients with comorbid 
bipolar diagnosis, psychosis, organic mental disorders, or devel-
opmental disorders. If there was a history of substance abuse, 
patients must have been in remission for at least 6  months. 
Current treatment with behavioral therapy, specifically expo-
sure and response prevention, for OCD excluded patients from 
participation. If patients were prescribed an antidepressant 
for major depression within the past 12  months, they were 
excluded. Further exclusion criteria included psychotropic 
medication other than a benzodiazepine or sleep aid within 2 
weeks of beginning the study, more than one adequate trial (at 
least 10 weeks at maximally tolerated dose) with another SNRI, 
previously known hypersensitivity to duloxetine or any of the 
inactive ingredients, treatment with an monoamine oxidase 
inhibitor within 14  days of randomization, and patients with 
uncontrolled narrow-angle glaucoma.
Schedule of Assessments and Study Instruments
Interested participants completed phone screens for 
study eligibility and were then evaluated at an initial visit 
(visit 1)  for inclusion/exclusion criteria. During visit 1, the 
Structured-Clinical Interview for Diagnostic and Statistical 
Manual of Mental Disorders Axis I disorders (First et al., 1995) 
was administered for diagnostic evaluation. The severity of 
OCD symptoms was assessed using the Y-BOCS (Goodman 
et al., 1989b 1989c), depressive and anxiety symptoms were 
assessed with the Beck Depression Inventory (BDI; Beck 
et al., 1961) and the Beck Anxiety Inventory (BAI; Beck et al., 
1988), and the Quality of Life, Enjoyment, and Satisfaction 
Questionnaire (Q-LES-Q; Endicott et al., 1993) was utilized to 
assess quality of life. Additionally, blood pressure was taken 
at each study visit to ensure it remained within normal 
ranges.
After visit 1, eligible patients began open-label treatment 
with duloxetine at 30 mg/d. They were seen for a follow-up visit 
(visit 2) after 1 week. At visit 2, patients were assessed and, if 
they were not experiencing significant adverse events, their 
dose was increased from 30 to 60 mg/d. Patients taking 60 mg/d 
then returned for assessment in 4 weeks (visit 3). At this time, if 
they were not experiencing significant adverse events, the dose 
was increased to 120 mg/d. If a patient was unable to tolerate 
120 mg/d, their dose was decreased back to 60 mg/d. Remaining 
assessment then occurred every 4 weeks (visits 4, 5, and 6). In 
total, this was a 17-week study with 12 weeks at the high dose 
believed to be necessary for response.
At each study visit following the initial visit, patients 
were assessed using the Y-BOCS, BDI, BAI, and Clinical Global 
Improvement scale (CGI; Guy, 1976). The Q-LES-Q was admin-
istered only at the first and last study visits. The primary study 
outcome measures were the Y-BOCS and CGI. The Q-LES-Q was 
considered a secondary measure, and the BDI and BAI were con-
sidered tertiary.
Data Analyses
Independent 2-tailed, paired t tests were used to assess the 
effects of duloxetine on all study outcome measures. Both com-
pleter and intention-to-treat (ITT) analyses were conducted. 
Completer analyses included subjects who completed all 6 
study visits (n = 12). ITT analysis included all participants who 
signed consent and completed visit 1 (n = 20). To complete the 
ITT analysis, the last visit completed was carried forward and 
treated as the final visit. Full responders were defined as those 
who had a decrease in Y-BOCS score by ≥25% AND a CGI score of 
<3 at the final study visit. Nonresponders were those who failed 
to satisfy either criterion of improvement.
Results
Sample Characteristics
Eleven (55%) of the 20 study participants were female. The 
mean age at the initiation of the study was 29.90 (SD = 10.66; 
range = 18–55) years. The mean age of onset of OCD was 15.35 
(SD = 10.479; range = 5–50) years, with a mean duration of illness 
of 14.80 (SD = 12.88; range = 1–46) years.
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ITT Analyses
Twenty participants (11 female) were included in the ITT 
analyses. All subjects were included in the ITT analysis, 
because all 20 enrolled completed their visit 1. The ITT analy-
sis was performed using the last observation carried forward 
method and included all eligible participants who received 
their medication after visit 1. Statistically significant (P < .05) 
changes in scale scores from visit 1 to visit 6 were reported 
for primary and secondary outcome measures (Table 1). Mean 
baseline Y-BOCS score for ITT was 27.45 (SD = 4.08) and the 
mean final Y-BOCS score was 20.45 (SD = 7.57). CGI scores were 
not taken at visit 1, so values from visit 2 were compared with 
the final CGI. The mean CGI score at final study visit was 2.70 
(SD  =  0.923), which corresponds to a value between “much 
improved” and “minimally improved.” Mean baseline Q-LES-Q 
for ITT was 70.14 (SD = 14.03) and mean final score was 74.55 
(SD  =  12.03), giving a t  =  -2.15 and a P value  =  0.045. Mean 
baseline BDI was 10.30 (SD = 6.98) and mean baseline BAI was 
10.70 (SD = 11.54), with mean final BDI being 6.95 (SD = 6.10) 
and mean final BAI being 6.75 (SD  =  7.05). BDI change was 
significant at P < .05, but BAI score was not. Of the 20 study 
participants, 7 (35%) were full medication responders and 9 
(45%) were nonresponders.
Completer Analyses
Twelve participants were included in the completer analy-
ses (6 female). Two participants were lost due to follow-up 
despite repeated attempts to contact them. One participant 
chose not to take the medication after completing visit 1 and 
signing the consent form. Five participants chose to discon-
tinue the study because of adverse events. Statistically sig-
nificant (P < .05) changes from visit 1 to visit 6 were reported 
for the primary and secondary outcome measures (Table 2). 
Mean baseline Y-BOCS score for completers was 28.33 
(SD = 4.66) and mean final Y-BOCS score was 18.5 (SD = 7.98). 
At visit 6, the mean CGI score was 2.17 (SD = .72), which cor-
responds to a rating between “much improved” and “mini-
mally improved.” Mean baseline Q-LES-Q for completers was 
70.50 (SD = 16.53) and mean final was 77.86 (SD = 12.40), giv-
ing a t  =  -2.30 and P value of 0.042. Mean baseline BDI was 
9.83 (SD = 8.16) and mean baseline BAI was 10.92 (SD = 13.09), 
with mean final BDI being 6.33 (SD  =  6.77) and mean final 
BAI being 4.91 (SD  =  5.70). BDI and BAI scores, the tertiary 
outcome measures, were not significant at P < .05. Of the 12 
participants who completed the open-label duloxetine treat-
ment, 7 (58.3%) were full medication responders and 3 (25%) 
were nonresponders.
Adverse Events
The most common adverse event was nausea (50% of subjects), 
followed by fatigue (41.2%), sexual dysfunction (23.1%), and 
headache (11.1%). There were no serious adverse events.
Blood pressure (measured in mmHg) was taken at each 
study visit. Independent, paired-samples t tests were run on 
both systolic and diastolic pressures. The baseline systolic was 
122.33 ± 13.38 for completers and 121.0 ± 14.71 for ITT, and at the 
final visit the systolic pressure was 124.42 ± 14.87 for completers 
and 123.1 ± 16.04 for ITT. It was found that systolic pressure did 
not significantly increase for either the completer group (P = .561; 
t = -0.599) or the ITT group (P = .382; t = -0.895). The baseline dias-
tolic was 71.25 ± 9.31 for completers and 73.15 ± 8.61 for ITT, and 
at the final visit the diastolic pressure was 79.83 ± 9.61 for com-
pleters and 78.50 ± 8.92 for ITT. Diastolic pressure did signifi-
cantly increase for both the completer group (P = .001; t = -4.288) 
and the ITT group (P = .008; t = -2.944).
Discussion
The results of this study support the efficacy of duloxetine in 
reducing severity of OCD symptoms, as 58.3% of the subjects 
who completed the study were full medication responders. 
Statistically significant improvement was reported for the pri-
mary and secondary outcome measures for both the completer 
and ITT analyses. However, in the ITT group, the observed 
7-point drop in Y-BOCS score is moderate. It should be noted that 
adverse events were relatively common and that 40% of the sub-
jects enrolled dropped out. However, duloxetine was relatively 
well tolerated by our completer study sample, with only 2 par-
ticipants requiring a reduction in dosage due to adverse events.
Although there are few data on SNRIs for the treatment of 
OCD, these previous data have suggested that SNRIs will prove 
useful for relief of OCD symptoms. The additional noradrener-
gic effects of the SNRIs could provide an additive advantage in 
treatment. Specifically, affecting multiple neurotransmitter sys-
tems could have additive value for the treatment of comorbid 
disorders. However, based on the frequency of adverse events 
observed in this clinical trial, duloxetine may be less tolerable 
than other SRIs and is certainly less tolerable than behavio-
ral therapy. Duloxetine is indicated for the treatment of major 
depressive disorder, which is commonly comorbid with OCD. 
Furthermore, duloxetine is helpful for managing symptoms of 
chronic pain. Somatic-obsessions, sometimes associated with 
real or imagined pain, are common in OCD. Also, symptoms of 
pain (eg, headaches and muscle tension) are common physi-
cal manifestations of anxiety. Duloxetine is FDA approved for 
Table 1. Intention-To-Treat Analyses
Rating 
Scale
Baseline 
(mean ± SD)
Final Visit 
(mean ± SD) t d.f. P value Cohen’s d
Y-BOCS 27.45 ± 4.08 20.45 ± 7.57 5.44 19 <.001 1.22
CGI 4.0 ± 0 2.70 ± .923 6.30 19 <.001 1.41
Q-LES-Q 70.14 ± 14.03 74.55 ± 12.03 −2.15 19 .045 0.48
BDI 10.30 ± 6.98 6.95 ± 6.10 3.20 19 .005 0.72
BAI 10.70 ± 11.54 6.75 ± 7.05 1.67 19 .112 0.37
Intention-to-treat (ITT) analyses (n = 20). All ITT analyses utilized the last 
observation carried forward method. BAI, Beck Anxiety Inventory; BDI, Beck 
Depression Inventory; CGI, Clinical Global Impressions Scale; Q-LES-Q, Quality 
of Life, Enjoyment, and Satisfaction Questionnaire; Y-BOCS, Yale-Brown Obses-
sive Compulsive Scale.
Table 2. Completer Analyses
Rating 
Scale
Baseline 
(mean ± SD)
Final Visit 
(mean ± SD) t d.f. P value Cohen’s d
Y-BOCS 28.33 ± 4.66 18.5 ± 7.98 6.71 11 <.001 1.94
CGI 4.00 ± 0 2.17 ± .72 8.84 11 <.001 2.55
Q-LES-Q 70.50 ± 16.53 77.86 ± 12.40 −2.30 11 .045 0.66
BDI 9.83 ± 8.16 6.33 ± 6.77 2.13 11 .056 0.62
BAI 10.92 ± 13.09 4.91 ± 5.70 1.80 11 .099 0.52
Completer analyses (n = 12). BAI, Beck Anxiety Inventory; BDI, Beck Depres-
sion Inventory; CGI, Clinical Global Impressions Scale; Q-LES-Q, Quality of Life, 
Enjoyment, and Satisfaction Questionnaire; Y-BOCS, Yale-Brown Obsessive 
Compulsive Scale.
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management of chronic lower back pain, osteoarthritis pain, 
diabetic peripheral neuropathic pain, and musculoskeletal pain. 
Given these indications, duloxetine is unique among SNRIs and 
therefore has promising implications as a novel pharmacologi-
cal treatment of OCD.
There are several weaknesses in this trial limiting the inter-
pretation of the data. The study was a small sample, with a 
recruitment goal of only 20 individuals, and an anticipated drop-
out rate of 40%. The 20 participants were consecutively recruited 
from 30 completed phone screens. Of the 30 phone screens, 13 
were male and 17 were female. Two of the 20 participants had 
comorbid Generalized Anxiety Disorder diagnoses. Excluding 
those 2 participants from t tests for Y-BOCS, BDI, BAI, CGI, and 
Q-LES-Q results did not change for either ITT or completer 
analyses. Also, the study was open-label, such that both inves-
tigators and participants were aware of the dosage they were 
receiving. This could have led to a placebo effect, increasing the 
response rate as subjects received increased doses of duloxe-
tine. Further research will be required to establish the optimal 
dosage of duloxetine for individual treatment.
Despite the limitations of the trial, this study is the first 
open-label investigation of duloxetine for the treatment of OCD. 
Double-blind, placebo-controlled studies with larger sample 
sizes are needed to further evaluate the efficacy of duloxetine 
for OCD. However, this investigation offers promising results for 
the use of an SNRI as treatment for OCD.
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